Palbociclib (75, 100, 125 milligram [mg]) + H3B-6545 (150, 300, 450 mg)
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Receptors, Estrogen
Conditions
Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Trial Timeline
Apr 1, 2020 → Mar 31, 2027
NCT ID
NCT04288089About Palbociclib (75, 100, 125 milligram [mg]) + H3B-6545 (150, 300, 450 mg)
Palbociclib (75, 100, 125 milligram [mg]) + H3B-6545 (150, 300, 450 mg) is a phase 1 stage product being developed by Eisai for Receptors, Estrogen. The current trial status is active. This product is registered under clinical trial identifier NCT04288089. Target conditions include Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms.
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04288089 | Phase 1 | Active |